UA105648C2 - Екструдати з голчатими активними речовинами - Google Patents

Екструдати з голчатими активними речовинами

Info

Publication number
UA105648C2
UA105648C2 UAA201108386A UAA201108386A UA105648C2 UA 105648 C2 UA105648 C2 UA 105648C2 UA A201108386 A UAA201108386 A UA A201108386A UA A201108386 A UAA201108386 A UA A201108386A UA 105648 C2 UA105648 C2 UA 105648C2
Authority
UA
Ukraine
Prior art keywords
extrudates
spicular
active substances
active substance
pharmaceutically active
Prior art date
Application number
UAA201108386A
Other languages
English (en)
Russian (ru)
Inventor
Венката-Рангарао Каніканті
Ханс-Юрген ХАМАНН
Петер КЛЯЙНЕБУДДЕ
Ріке Вітцлеб
Original Assignee
Баєр Інтеллекчуел Проперті Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41785839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105648(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Баєр Інтеллекчуел Проперті Гмбх filed Critical Баєр Інтеллекчуел Проперті Гмбх
Publication of UA105648C2 publication Critical patent/UA105648C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

Винахід стосується екструдатів, що містять принаймні одну фармацевтично активну речовину в формі голок, причому співвідношення між розміром частинок голчатої фармацевтично активної речовини та діаметром штрангу становить щонайменше 1:25, а також застосування цих екструдатів для одержання лікарських засобів.
UAA201108386A 2008-12-05 2009-11-24 Екструдати з голчатими активними речовинами UA105648C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008060472 2008-12-05
PCT/EP2009/008341 WO2010063387A1 (de) 2008-12-05 2009-11-24 Extrudate mit nadelförmigen wirkstoffen

Publications (1)

Publication Number Publication Date
UA105648C2 true UA105648C2 (uk) 2014-06-10

Family

ID=41785839

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108386A UA105648C2 (uk) 2008-12-05 2009-11-24 Екструдати з голчатими активними речовинами

Country Status (28)

Country Link
US (1) US20120034273A1 (uk)
EP (1) EP2373287B1 (uk)
JP (2) JP5860284B2 (uk)
KR (1) KR20110096145A (uk)
CN (1) CN102238940B (uk)
AR (1) AR075106A1 (uk)
AU (1) AU2009321822B2 (uk)
BR (1) BRPI0922302B8 (uk)
CA (1) CA2745456A1 (uk)
CL (1) CL2011001207A1 (uk)
CO (1) CO6440550A2 (uk)
CR (1) CR20110285A (uk)
DO (1) DOP2011000160A (uk)
EC (1) ECSP11011080A (uk)
ES (1) ES2685472T3 (uk)
HK (1) HK1163547A1 (uk)
IL (1) IL212846A0 (uk)
MX (1) MX2011005572A (uk)
NI (1) NI201100103A (uk)
NZ (1) NZ593217A (uk)
PE (1) PE20120182A1 (uk)
RU (1) RU2549450C2 (uk)
SV (1) SV2011003919A (uk)
TW (1) TWI522114B (uk)
UA (1) UA105648C2 (uk)
UY (1) UY32287A (uk)
WO (1) WO2010063387A1 (uk)
ZA (1) ZA201104145B (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CA2906295C (en) * 2013-03-15 2019-01-22 Argenta Manufacturing Limited Chewable formulation
IN2013MU03583A (uk) * 2013-11-14 2015-07-31 Cipla Ltd
CN110996920A (zh) 2017-07-26 2020-04-10 太杰先软嚼有限责任公司 用于兽医应用的无淀粉软咀嚼物
US20230372249A1 (en) 2020-09-04 2023-11-23 Elanco Us Inc. Palatable formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4402752B2 (ja) * 1997-05-19 2010-01-20 大日本住友製薬株式会社 免疫増強製剤
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
RU2004106619A (ru) * 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
CN1662223A (zh) * 2002-06-27 2005-08-31 西拉格股份公司 含水溶性活性成分的球形微丸
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
DK1566173T3 (da) * 2004-02-20 2006-12-27 Mattern Udo Farmaceutisk sammensætning til oral anvendelse og fremgangsmåde til fremstilling deraf
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JPWO2006090640A1 (ja) * 2005-02-23 2008-07-24 太陽化学株式会社 アミノ酸含有錠剤組成物および錠剤の製造方法
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CN101590020B (zh) * 2008-05-30 2012-02-08 上海新菲尔生物制药工程技术有限公司 一种对氨基水杨酸钠结肠定位给药系统

Also Published As

Publication number Publication date
JP2015134812A (ja) 2015-07-27
TWI522114B (zh) 2016-02-21
EP2373287A1 (de) 2011-10-12
ZA201104145B (en) 2012-09-26
CO6440550A2 (es) 2012-05-15
SV2011003919A (es) 2011-08-28
TW201031422A (en) 2010-09-01
JP5860284B2 (ja) 2016-02-16
NI201100103A (es) 2012-04-16
CA2745456A1 (en) 2010-06-10
RU2011127248A (ru) 2013-01-10
NZ593217A (en) 2013-05-31
US20120034273A1 (en) 2012-02-09
AU2009321822B2 (en) 2015-04-16
KR20110096145A (ko) 2011-08-29
CN102238940A (zh) 2011-11-09
CN102238940B (zh) 2014-07-30
DOP2011000160A (es) 2011-06-30
BRPI0922302B1 (pt) 2020-09-15
CL2011001207A1 (es) 2011-10-28
HK1163547A1 (en) 2012-09-14
JP2012510956A (ja) 2012-05-17
AU2009321822A1 (en) 2011-06-30
MX2011005572A (es) 2011-06-16
PE20120182A1 (es) 2012-02-24
AR075106A1 (es) 2011-03-09
ECSP11011080A (es) 2011-06-30
CR20110285A (es) 2011-09-27
BRPI0922302B8 (pt) 2021-05-25
WO2010063387A1 (de) 2010-06-10
EP2373287B1 (de) 2018-05-30
UY32287A (es) 2010-06-30
RU2549450C2 (ru) 2015-04-27
BRPI0922302A2 (pt) 2016-01-05
IL212846A0 (en) 2011-07-31
ES2685472T3 (es) 2018-10-09

Similar Documents

Publication Publication Date Title
MX2010008138A (es) Forma de dosis farmaceutica.
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
EP2177210A4 (en) METHOD FOR THE PRODUCTION OF MICROPARTICLES FOR INCLUSION IN THE BODY, MICROPARTICLES FOR INCLUSION IN THE BODY, DISPERSION AND MEDICAL COMPOSITION THEREWITH
SG2014009252A (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
ZA201101097B (en) Pharmaceutical composition of n-[2,4-bis (1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and administration thereof
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
IL204887A (en) Acetamide History, Pharmaceuticals Containing Them, Methods of Preparing and Using It in the Preparation of Diabetes Medications
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
EP2154166A4 (en) FINE PARTICLES OF MOLECULAR SPONSORED GEL, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
IL198845A (en) An extended-release peptide preparation, a process for its preparation and use for drug preparation
ZA201006639B (en) Nanoparticle carriers for drug administration and process for producing the same
UA105648C2 (uk) Екструдати з голчатими активними речовинами
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
WO2008132682A3 (en) Improved vitamin d content uniformity in pharmaceutical dosage forms
ZA200900017B (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
ZA200805793B (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
UA92604C2 (uk) Композиція стансопорфіну з фізіологічною осмотичною концентрацією та її застосування
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
WO2007089926A3 (en) Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
IL204957A (en) Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten
EP2047851A4 (en) DRUG-FORMULATION WITH A FIBRATE MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF
PL1877035T3 (pl) Kompozycja farmaceutyczna i postać galenowa szybko rozpadająca się w jamie ustnej oraz sposób jej wytwarzania
ZA200900728B (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
UA36724U (uk) Склад сухої мікстури від кашлю